1.0hollandbiohttps://www.hollandbio.nl/en/rich600338<blockquote class="wp-embedded-content" data-secret="unoSAAdkqk"><a href="https://www.hollandbio.nl/en/event-en/ra2day-anniversary-special/">RA2day: regualtory impact on oncology approvals</a></blockquote><iframe sandbox="allow-scripts" security="restricted" src="https://www.hollandbio.nl/en/event-en/ra2day-anniversary-special/embed/#?secret=unoSAAdkqk" width="600" height="338" title="“RA2day: regualtory impact on oncology approvals” — hollandbio" data-secret="unoSAAdkqk" frameborder="0" marginwidth="0" marginheight="0" scrolling="no" class="wp-embedded-content"></iframe><script> /*! This file is auto-generated */ !function(d,l){"use strict";l.querySelector&&d.addEventListener&&"undefined"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!/[^a-zA-Z0-9]/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret="'+t.secret+'"]'),o=l.querySelectorAll('blockquote[data-secret="'+t.secret+'"]'),c=new RegExp("^https?:$","i"),i=0;i<o.length;i++)o[i].style.display="none";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute("style"),"height"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):"link"===t.message&&(r=new URL(s.getAttribute("src")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener("message",d.wp.receiveEmbedMessage,!1),l.addEventListener("DOMContentLoaded",function(){for(var e,t,s=l.querySelectorAll("iframe.wp-embedded-content"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute("data-secret"))||(t=Math.random().toString(36).substring(2,12),e.src+="#?secret="+t,e.setAttribute("data-secret",t)),e.contentWindow.postMessage({message:"ready",secret:t},"*")},!1)))}(window,document); //# sourceURL=https://www.hollandbio.nl/wp-includes/js/wp-embed.min.js </script> See how data substantiates the impact of Regulatory Affairs on Oncology approvals  In the past decade, more than 25% of drug approvals were for treatment of cancer. Much can be learned from the regulatory pathways taken and regulatory tools used. Have regulatory initiatives to speed up development and authorization of cancer drugs lived up to the expectations? […]https://www.az-regulatory.com/images/logos/RA2Day_logo_10anniversary_sp.png